Abstract

This meta-analysis aims to assess the antihypertensive effectiveness, safety, and cost-effectiveness of allisartan to support its clinical use and promote rational antihypertensive drug usage. A meta-analysis was registered on International Prospective Register of Systematic Reviews (CRD42022370300) and collected allisartan research on hypertensive patients from sources like PubMed, Cochrane library, China National Knowledge Infrastructure, Wanfang and Vipshop databases from the establishment of the databases to September 2022. Review manager and Stata software evaluated the literature quality, analyzed the outcome indicators, assessed publication bias via Egger's test, and conducted pharmacoeconomic evaluation. Inclusion criteria covered 14 studies with 2125 patients, including 734 allisartan-treated patients. When compared with other angiotensin receptor blocker antihypertensives, allisartan showed reduced systolic blood pressure (5.46 mmHg, 95 % confidence interval: 1.99~8.93, p<0.001) and diastolic blood pressure (2.90 mmHg, 95 % confidence interval: -0.28~6.08, p<0.001). However, this was clinically within the normal blood pressure fluctuations and did not reach the threshold for adverse reactions (relative risk=0.74, 95 % confidence interval: 0.53~1.04, p=0.953). Safety and efficacy of allisartan were compared with other angiotensin receptor blocking drugs. Cost-minimization analysis indicated favorable economics for allisartan. Allisartan exhibits antihypertensive safety and efficacy with other angiotensin receptor blocker antihypertensive drugs, while also displaying costeffectiveness. This supports its clinical use and rationalizes antihypertensive drug choices.